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Abstract
An accurate assessment of prostate tumour burden supports appropriate treatment
selection, ranging from active surveillance through focal therapy, to radical wholeprostate therapies. For selected patients, knowledge of the three-dimensional locations
and sizes of prostate tumours on pre-procedural imaging supports planning of effective
focal therapies that preferentially target tumours, while sparing surrounding healthy
tissue. In the post-prostatectomy context, pathologic measurement of tumour burden in
the surgical specimen may be an independent prognostic factor determining the need for
potentially life-saving adjuvant therapy. An accurate and repeatable method for tumour
volume assessment based on histology sections taken from the surgical specimen would
be supportive both to the clinical workflow in the post-prostatectomy setting and to
imaging validation studies correlating tumour burden measurements on preprostatectomy imaging with reference standard histologic tumour volume measurements.
Digital histopathology imaging is enabling a transition to a more objective
quantification of some surgical pathology assessments, such as tumour volume, that are
currently visually estimated by pathologists and subject to inter-observer variability.
Histologic tumour volume measurement is challenged by the traditional 3–5 mm sparse
spacing of images acquired from sections of radical prostatectomy specimens. Tumour
volume estimates may benefit from a well-motivated approach to inter-slide tumour
boundary interpolation that crosses these large gaps in a smooth fashion. This thesis
describes a new level set-based shape interpolation method that reconstructs smooth 3D
shapes based on arbitrary 2D tumour contours on digital histology slides. We measured
the accuracy of this approach and used it as a reference standard against which to
compare previous approaches in the literature that are simpler to implement in a clinical
workflow, with the aim of determining a method for histologic tumour volume estimation
that is both accurate and amenable to widespread implementation. We also measured the
effect of decreasing inter-slide spacing on the repeatability of histologic tumour volume
estimation. Furthermore, we used this histologic reference standard for tumour volume to
measure the accuracy, inter-observer variability, and inter-sequence variability of prostate
ii

tumour volume estimation based on radiologists’ contouring of multi-parametric
magnetic resonance imaging (MPMRI).
Our key findings were that (1) simple approaches to histologic tumour volume
estimation that are based on 2- or 3-dimensional linear tumour measurements are more
accurate than those based on 1-dimensional measurements; (2) although tumour shapes
produced by smooth through-slide interpolation are qualitatively substantially different
from those obtained from a planimetric approach normally used as a reference standard
for histologic tumour volume, the volumes obtained were similar; (3) decreasing interslide spacing increases repeatability of histologic tumour volume estimates, and this
repeatability decreases rapidly for inter-slide spacing values greater than 5 mm; (4) on
MPMRI, observers consistently overestimated tumour volume as compared to the
histologic reference standard; and (5) inter-sequence variability in MPMRI-based tumour
volume estimation exceeded inter-observer variability.

Keywords:

Prostate cancer, digital histopathology, radical prostatectomy, tumour

volume, level set method, shape interpolation, multi-parametric magnetic resonance
imaging.
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Chapter 1
1

General introduction and literature review

1.1

Motivation and clinical overview
Prostate cancer (PCa) is the most common non- cutaneous cancer and the second

leading cause of cancer death among men. One in seven Canadian men will likely
develop PCa within his lifetime. It is estimated that in 2014, 23,600 men will be
diagnosed with PCa and 4,000 men will die of PCa in Canada [1]. Most PCa is typically
slow-growing, which means that it takes several years to become large enough to be
detectable and men who develop PCa may live many years without any symptoms. It is
important that screening is done regularly in men so that if they develop PCa, appropriate
action can be taken. In addition, if PCa is detected at an early stage, it is highly treatable
and in most cases, curable [2]. Screening based on serum prostate-specific antigen (PSA)
testing and digital rectal examination (DRE), followed by 2D transrectal ultrasound
(TRUS)-guided biopsy has resulted in the detection of tumours at an earlier stage.
However, due in part to the high sensitivity and low specificity PSA testing and
sampling issues related to 2D TRUS-guided biopsy, PCa is currently considered to be an
over-diagnosed disease [3]. This potentially leads to aggressive whole-gland therapies
(radical radiotherapy or prostatectomy surgery) with associated life-changing side effects.
On the other hand, there is a 40% rate of discrepancy between the Gleason grade
estimated at biopsy and the true grade at prostatectomy [4, 5]. In cases where the grade is
underestimated, the patient could be incorrectly placed on active surveillance, with the
psychological burden related to untreated PCa [3, 6]. After a patient has been diagnosed
with PCa, many challenges exist regarding treatment. The first is the selection of
appropriate treatment for each individual patient. The second is, for patients who undergo
radical prostatectomy surgery to remove the prostate, determining whether additional
treatment is needed, and if so, when to apply this treatment. The flow diagram in Figure
1.1 shows some of the treatment options for organ-confined PCa.
1

Active
surveillance

Lower
risk

Organ-confined
prostate cancer
diagnosis (positive
biopsy)
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prostatectomy
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High grade,
e.g. ≥G8

Intermediate grade,
e.g. G7
Focal therapy delivery

Figure 1.1. Schematic diagram showing some of the treatment options for organconfined prostate cancer.
There are several different therapeutic modalities for organ-confined prostate
cancer treatment, with the appropriate choice depending on the risk level of the patient.
Active surveillance may be appropriate if the cancer is small, low-grade, expected to be
slow-growing, and confined to one area of the prostate. During active surveillance, PCa is
monitored closely for any changes and no immediate treatment may be required. As there
are no invasive procedures and drugs used, there are no immediate side effects from
active surveillance. However, patients on active surveillance can feel anxiety regarding
the lack of treatment for their cancer, and may be concerned about the potential for their
cancer to change into a more life-threatening form. For higher risk patients, radical
prostatectomy (RP) may be needed. RP is a surgical procedure to remove the prostate
gland plus a margin of tissue around it, including the seminal vesicles. In cases of truly
organ-confined cancer with a clear surgical margin, RP has the advantage of total
excision of the cancerous tissue from the patient. However, RP has side effects including
erectile dysfunction and urinary incontinence. It has been estimated that approximately
2

40% of men with organ-confined PCa undergo RP, with nearly 80,000 surgeries per year
in the United States [7]. For medium risk patients with tumours localized to specific
regions within the prostate, focal therapy may be appropriate. Focal therapy is an
emerging type of treatment and may serve as a middle ground between active
surveillance and RP for patients with low to intermediate-risk cancers [8]. It involves the
treatment of only the dominant intraprostatic lesion(s), while minimizing damage to
surrounding healthy tissue. However, focal therapy is not currently used routinely in the
clinical workflow [7].
It has been shown that for approximately 35% of patients who underwent RP,
there was evidence of recurrence as measured by an increase in the PSA level (beyond
0.2 ng/mL) in the blood [9]. This is known as biochemical failure, or BCF. After BCF, it
may be possible to cure the patient by applying salvage therapy, using modalities
including radiation, salvage RP (in cases of failure of primary radiation therapy),
cryoablation, and high-intensity focused ultrasound (HIFU). If BCF is anticipated based
on adverse findings on surgical pathology, adjuvant therapy may be applied shortly after
RP. In adjuvant therapy, the physician does not wait for BCF to occur; therapy is applied
as soon as possible after RP surgery. Therefore, the pathologist’s assessment of the
surgically removed prostate may identify the need for adjuvant therapy [10]. If the
pathology report contains findings that suggest strongly that the cancer may recur, such
as one or more large-volume tumours, adjuvant therapy may be indicated.
The decision of whether to use adjuvant therapy is important and challenging.
Adjuvant therapy cannot be used for all patients due to the serious side effects that can
occur, but can be life-saving for appropriately selected patients. Planning of postprostatectomy adjuvant or salvage treatment depends on tumour volume (TV), Gleason
grades of the tumours, and the focality and location of the tumours in the prostatectomy
specimen [11]. In addition, planning for focal therapy requires that the tumour targets be
delineated on imaging, with a suitable margin to account for treatment delivery
uncertainty, and there are currently no generally accepted guidelines for physicians to
follow in doing this task. An accurate and repeatable assessment of tumour volume in the
prostatectomy specimen would be valuable to therapy selection for RP patients, and also
3

useful to imaging-histology co-registration approaches to the determination of suitable
treatment margins for focal therapy [12-14].

1.2
1.2.1

The prostate gland
Anatomy and physiology
The normal prostate gland is about the size of a walnut and somewhat conical in

shape within the male reproductive system. It is located in front of the rectum and
directly beneath the bladder (Figure 1.2 (a)). The main function of the prostate is to
produce fluid that forms part of the semen. On both sides of the prostate are
neurovascular bundles which, if damaged during cancer treatment (e.g. surgery, radiation
therapy), could lead to erectile dysfunction (Figure 1.2 (b)) [15].

Figure 1.2. (a) Sagittal view of prostate and nearby organs, depicting its position relative
to the bladder. (b) Sagittal view of prostate showing the inside of the prostate, urethra,
rectum, and bladder [16].

4

The prostate is divided into three distinct anatomical regions. The peripheral zone
(PZ) covers 70% of the glandular prostate. It is located in the outer area of the prostate,
close to the rectum. The central zone (CZ) constitutes 25% of the glandular prostate. It is
located in the center of the prostate with its base at the bladder neck and its tip at the
verumontanum. Finally, the transition zone (TZ) covers 5% of the glandular prostate. It is
above the CZ and also includes two lobes located anteriorly between the proximal urethra
and the lateral parts of the PZ (Figure 1.3). Most studies have shown that the PZ is the
most common site for prostate cancer foci, whereas common abnormalities such as
benign prostatic hyperplasia (BPH) develop mainly in the CZ and TZ [17]. BPH
symptoms are often similar to cancer; however BPH involves the noncancerous
enlargement of the prostate gland and typically occurs in older men. If the prostate’s size
grows too large, it may press on the bladder, causing frequent urination, or it may
constrict the urethra and impede urine flow [15].

Figure 1.3. Schematic diagram depicting the prostate zones in the sagittal plane. 1 = PZ
(peripheral zone), 2 = CZ (central zone), 3 = TZ (transitional zone), 4 = anterior
fibromuscular zone, B = bladder, and U = urethra [18].
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1.2.2

Prostate cancer
PCa results from an oncogenic, or dysplastic, change in the prostate glandular

tissue. The tumour foci are often microscopic and heterogeneous [2]. PCa is typically a
slow growing cancer and some men who develop PCa may live many years without
having any cancer detected. However, there are cases of aggressive PCa where cancer
cells may metastasize from the prostate to other parts of the body. PCa is mostly
asymptomatic in its early stages, however other symptoms can arise during later stages,
which cause frequent urination, blood in the urine, and pain in urinating. Urinary
dysfunction is associated with the fact that the prostate gland surrounds the urethra.
Consequently, any changes within the gland (including prostate enlargement) can directly
affect urinary function and can pinch off the urethra and/or generate pressure on the
bladder (Figure 1.4). Cancerous growth in the prostate can either be benign or malignant.
PCa is generally considered to be a malignant tumour and the prostate tends to enlarge
asymmetrically in the presence of PCa. However, in BPH, the prostate mainly tends to
enlarge centrally, and the prostate shape remains more uniform.

Figure 1.4. Schematic diagram depicting a normal prostate and a prostate enlarged due to
BPH. A normal prostate does not block urine flow from the bladder, whereas an enlarged
prostate blocks urine flow and presses on the urethra and bladder [19].

6

1.2.3 Prostate cancer screening
Early detection and accurate preoperative assessment of prostate cancer are
essential to the selection of appropriate treatment [20]. Since if cancer is detected too late,
it may become exophytic and subsequently metastasize to the rest of the body, some
screening tests such as PSA, DRE and 2D TRUS-guided biopsy have been used to detect
the presence of cancer in its earliest stages. The PSA test measures the amount of PSA in
the blood. PSA was first identified in seminal fluid by Hara in 1969 [21]. This antigen is
produced within the prostate gland and is found in the blood in very small concentrations.
Higher blood levels of PSA may occur in the presence of cancer and can also indicate
other prostate conditions such as BPH. The normal range for PSA is generally considered
to be 0 to 4 ng/ml [22]. However, more recent studies have shown that the PSA test is not
specific to PCa and many men with higher PSA levels do not have prostate cancer; this
can lead to false-positive results. Some men with PSA levels below 4 ng/ml have prostate
cancer; this can lead to false-negative results [1, 22, 23]. In most cases, the patient is
referred for further investigation (e.g. biopsy) when PSA levels rise above 4 ng/ml [24].

Figure 1.5. Schematic diagram depicting the digital rectal exam [26].
A DRE is a physical examination performed by manual palpation of the prostate
to detect any irregularities in size, shape, and texture, in an effort to distinguish PCa and
non-cancerous conditions such as BPH. In the DRE test, the physician inserts a gloved
7

finger into the rectum to palpate the prostate gland; during the test, the patient may feel
temporary discomfort. The DRE test is not very sensitive for detection of small, earlystage tumours. Furthermore, it is limited by the physician’s access to mainly the posterior
portion of the gland (Figure 1.5) [25]. If the result of the DRE test is abnormal, further
testing is required to determine whether cancer is present.
Both the DRE and PSA tests are very easy to perform, inexpensive, require little
time, and are not associated with any significant risks. PCa detected as a result of PSA
screening is often at an earlier, more treatable stage.
A 2D transrectal ultrasound (TRUS)-guided prostate biopsy (Figure 1.6) is the
clinical standard for diagnosis, and is usually employed when the results of a DRE and/or
PSA test are suspicious for cancer. It is performed by inserting an end-firing or sidefiring ultrasound transducer probe into the patient’s rectum to acquire prostate images by
manipulating the transducer probe against the rectal wall. Once the probe is positioned, a
biopsy needle loaded into a biopsy gun is attached to the probe through a needle guide
that keeps the needle with in the 2D imaging plane of the transducer. A small biopsy
"core" of tissue is sampled near the needle tip when the biopsy gun is fired, and these
tissue cores are sent for histopathological analysis to detect and grade cancer. The
standard needle size is 18 gauge (1.2 mm outer diameter, 1.0 mm inner diameter) [27].
A typical pattern of biopsy targets is the sextant (Figure 1.7), wherein six biopsies
are taken from the right and left upper, middle, and lower lobes [26]. 2D TRUS has
limitations of poor cancer visualization and biopsy guidance, contributing to a reported
false negative rate of 34% [27]. It has become clear that TRUS imaging may not be
sufficient for prostate biopsy target localization, and it is worthwhile to explore
alternative imaging modalities for this purpose.
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Figure 1.6. Schematic diagram depicting the TRUS-guided biopsy procedure (courtesy
of the National Cancer Institute, USA) [19].
It has been shown that in many men with PCa, significant cancer was missed on
initial biopsy sampling, motivating more extensive sampling of the prostate to exclude
under-sampled significant cancer [29]. Although there is no controversy that tumour
volume in needle biopsy specimens should be reported, there is no consensus regarding
which method of tumour quantification should be adopted [30]. A single biopsy session
yields approximately 12 cylindrical 1 mm × 18 mm tissue samples and therefore provides
a tenuous estimate of tumour burden only under a strong set of assumptions. Emerging
evidence suggests that imaging may permit accurate assessment of PCa burden with
implications for screening and targeting treatment [31]. These challenges motivate the
need to assess tumour volume better on imaging, which is the focus of the work described
in Chapter 3.
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Figure 1.7. A diagram of the prostate, viewed from the posterior side, to illustrate sextant
biopsy [32].

1.3

Prostate cancer tumours

1.3.1 Prostate cancer tumour volume for prognosis
Many studies of PCa have investigated the relationship between tumour
size/volume measurement and prognosis. Histopathological analysis of PCa features in
RP specimens provides information that can predict the future course of the disease [3335]. After RP, standard prognostic parameters regarding PCa progression include the
overall Gleason score [36], the presence of extracapsular extension (ECE), seminal
vesicle invasion (SVI), pathological staging, status of the surgical margins, and tumour
volume [37]. In some studies, some of these predictors have been shown to be related,
such as the Gleason grade and tumour volume, and the margin status and pathological
stage [38, 39]. However, the question of whether tumour volume is an independent
prognostic factor has remained controversial [40-42]. Some studies have shown that
tumour volume is an independent prognostic parameter and recommend its use for
supporting treatment selection [43]. On the other hand, other studies have shown that
tumour volume is not able to independently provide additional information regarding
cancer progression, if Gleason grade and pathological stage are known [41]. Some studies
have failed to demonstrate the significance of tumour volume as an independent
prognostic factor [44, 45]. Differences between study cohorts and the use of different
methods for tumour volume estimation in different studies could be contributing factors
10

to these conflicting results regarding tumour volume. If tumour volume was widely
considered to be an independent prognostic parameter, pathologists could justify its
routine measurement and clinical reporting. However, to determine whether it is indeed
an independent prognostic parameter, a standard method for tumour volume
measurement that is accurate, repeatable, and can be widely implemented in the clinical
workflow is needed. A 2009 International Society of Urological Pathology Consensus
Conference included 116 genitourinary pathologists from 23 countries and concluded
that, “…in view of the potential importance of tumour size as a prognostic parameter,
coupled with the recent advances in imaging technology, it may prove necessary to
embrace more sophisticated methods for measuring tumour [size]. This was considered of
some importance as some argued that tumour size may become more important as a
defining parameter for both clinical and pathological staging.” [46].

1.3.2 Prostate cancer tumour volume assessment using 2D digital
histopathology imaging
PCa tumour volumes in RP specimens were first reported in 1986 [39]. The
traditional RP process includes tissue fixation in 10% buffered formalin for 12–48 hours,
followed by slicing into 3–5 mm thick tissue sections which are subsequently embedded
in paraffin blocks. 4–5 µm thick sections are then cut with a microtome from each block
face for hæmatoxylin and eosin (H&E) staining [47]. The pathologist then conducts a
microscopic examination of the sections. Each tumour is characterized in several ways,
including by location within the prostate, volume, and degree of differentiation [10]. The
pathology report provides essential information on prognostic characteristics relevant for
making clinical decisions regarding the need for further treatment.
The advent of whole-slide scanners is ushering in a new era in clinical pathology,
permitting the development of a digital environment for the management and assessment
of pathological images. Many scanners can digitally scan slides at diagnostic resolution
(0.25 µm per pixel) [48], with some scanners capable of higher resolutions of up to 100×
magnification (0.14 µm per pixel). Such devices open the possibility for the integration of
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computational tools into the digital pathology workflow in order to enable quantitative
assessments and enhancing clinical practice [49].
Whole-mount digital histology sections have been proposed as a reference
standard for evaluating tumour size, location, grade, and multifocality, and may permit
more accurate assessment of tumour volume where conventional sampling by biopsy is
difficult. A sample contoured whole-mount histopathology image is shown in Figure 1.8.
In the research study from which this slide was obtained, the pathologist contoured and
graded (using different coloured contours) all of the lesions on the image, as well as some
benign observations.

Figure 1.8. Sample contoured whole-mount, H&E-stained histopathology image. Colour
code is as follows. Brown: low-grade cancer. Gray, dark green, purple: regions
containing several different grades of cancer, all including some high-grade cancer.
Cyan: extraprostatic extension of tumour. Blue: atrophy (benign). Light green: prostatic
intraepithelial neoplasia (benign).
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1.3.3 Prostate cancer tumour volume assessment using magnetic
resonance imaging
Although imaging findings alone are not adequate for the primary diagnosis of
PCa, it has been shown that imaging could deliver richer 3D information, complementary
to the histological diagnosis. Several investigations have suggested that imaging could be
able to accurately define tumour margins that would provide tumour localization, size
estimation, real-time monitoring, and follow-up [50]. Among current imaging modalities,
magnetic resonance imaging (MRI) is gaining acceptance as the best imaging modality
for detecting and staging PCa due to the excellent anatomical and functional images that
can be obtained [51]. 3 Tesla (T) MRI, with its higher signal-to-noise ratios and higher
spatial resolution, has shown better PCa detectability as compared with 1.5 T MRI [52],
but the use of 3 T MRI to estimate tumour volume has not been widely assessed.
Multi-parametric MRI (MPMRI), with its morphological and functional pulse
sequence capabilities, has been recommended for the accurate assessment of prostate
tumour burden. Typical pulse sequences used for PCa imaging include T2-weighted
(T2W), diffusion-weighted (DW) and dynamic contrast enhanced (DCE) images [46].
T2W MRI essentially gives anatomical information about the prostate [53], DCE MRI
allows the visualization of vascular permeability and perfusion [54], and DW MRI
provides information regarding tissue cellular density and membrane integrity [55].
MPMRI has been recommended for PCa diagnosis, localization, and staging [53].
However, the accuracy and inter-observer variability of prostate tumour volume
estimation based on separate expert contouring of each of the T2W, DCE, and DW MRI
sequences acquired using an endorectal coil at 3 T is relatively under-explored.

1.3.4 Methods for prostate tumour volume measurement
In current clinical practice, prostate tumour volume is assessed visually by
pathologists; it is challenging to report quantitatively and is subject to observer variability
[46, 56]. 3D quantification is challenged by the conventional 3–5 mm inter-slide spacing
which is used in clinical pathology for reasons of cost and a need to archive tissue for
future diagnosis [47]. To address this challenge, several methods that are amenable to
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implementation in a clinical pathology workflow have been reported previously for
prostate tumour volume estimation on histology and are described as follows. (1) Cubic
volume (CV) method: tumour volume is estimated as ℎ × ℎ ℎ × 

ℎ,

where ℎ is the length of the greatest diameter the tumour, ℎ ℎ is the length of the
minor axis across the largest area, and 

ℎ is calculated by multiplying the inter-slide

spacing by the number of slices containing any tumour [57]. (2) Maximum tumour
diameter (MTD) method: tumour size is estimated as its ℎ [58]. (3) Estimated square
area (ESA) method: tumour size is estimated as ℎ × ℎ ℎ. These simple
approaches are valuable if they can be shown to be correlated to a trusted measure of
tumour volume, since their dependence on only a few linear measurements makes them
relatively straightforward to implement in a clinical workflow.
A typically-used reference standard for tumour volume on prostate digital
histology requires that the tumour be contoured on every slide on which it appears [59].
Using this method, tumour volume on digital pathology images is estimated as the sum of
within-slide tumour areas multiplied by the inter-slide spacing [60]. However, due to the
large difference between the slice thickness (4–5 µm) and the slide spacing (3–5 mm),
this approach can produce sharp changes in the tumour surface along the direction
orthogonal to the slides. As discussed in Section 1.5, one of the objectives of this thesis is
to develop a method for prostate tumour shape interpolation that produces smooth and
more plausible tumour boundaries.
On MPMRI, two different approaches have been reported previously for prostate
tumour volume measurement. (1) 2D slice-by-slice method: After outlining the regions
that are suspicious for cancer on each 2D MRI plane on which the tumour appears, the
areas of these regions are multiplied by the MRI plane thickness to calculate the tumour
volume [61]. (2) 3D method: The boundary of the 3D region that is suspicious for cancer
is defined with subvoxel precision by manipulation of the vertices of a 3D triangle mesh
enclosing the region. The tumour volume is then estimated as the volume enclosed by the
3D triangle mesh [61].
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1.4

Hypothesis
The central hypotheses of this thesis are that (1) tumour size estimates based on

the MTD, ESA, and CV methods can be used to obtain accurate estimates of prostate
tumour volume on histology; (2) repeatability of histologic tumour volume estimation
increases with decreasing inter-slide spacing; and (3) radiologists can accurately and
repeatably estimate prostate tumour volume by contouring suspicious regions on
MPMRI. Hypotheses (1) and (3) will be tested using the nearest-neighbour approach and
a newly-developed level-set based smooth shape interpolator as reference standards on
histology imaging.

1.5

Objectives
To test the central hypotheses, this thesis has the following objectives:
1. To develop a method based on a level set shape representation for estimation of

smooth 3D prostate tumour shapes, based on sparse tumour contours on 2D histology
images.
2. To compare tumour volumes obtained from the level set approach to those
obtained using the nearest-neighbour approach, which is typically used as a reference
standard.
3. To compare tumour volumes obtained from the MTD, ESA, and CV
approaches to tumour volumes obtained from the nearest-neighbour and level-set based
approaches.
4. To perform a simulation testing the impact of varying inter-slide spacing on the
repeatability of histologic tumour volume estimates.
5. To compare tumour volumes obtained from radiologists’ 3D contouring of
T2W, DCE, and ADC MR images to corresponding histologic tumour volumes from the
same patients.

15

6. To measure the inter-observer and inter-sequence variability in tumour volumes
obtained from radiologists’ 3D contouring of T2W, DCE, and ADC MR images.

1.6

Thesis outline

1.6.1 Chapter 2: Evaluation of the difference between inter-slide
interpolation methods for prostate tumour measurement on 2D
digital histopathology
Digital pathology imaging enables imaging-pathology fusion to validate imaging
for focal therapy planning, as well as quantification of surgical pathology assessments
such as tumour volume, that are currently visually estimated and subject to observer
variability. The computation of tumour volume and shape from digitized images of 4
micron histology sections acquired with 3–5 mm spacing is complicated by this large
image spacing:thickness ratio, requiring a plausible through-slide shape interpolation. In
this chapter, we describe our developed level set (LS)-based interpolation method that
produces smooth interpolations of arbitrary shapes. This chapter addresses objectives 1
through 4 as described in Section 1.5.
A preliminary version of this chapter has been published as “Toward Quantitative
Digital Histopathology for Prostate Cancer: Comparison of Inter-Slide Interpolation
Methods for Tumour Measurement,” by M. Salarian, M. Shahedi, E. Gibson, M. Gaed,
J.A. Gomez, M. Moussa, G.S. Bauman, A.D. Ward, in the proceedings of SPIE Medical
Imaging 2013.
A full version of this chapter will be submitted as, “Toward Quantitative Digital
Histopathology for Prostate Cancer: Comparison of Inter-Slide Interpolation Methods for
Tumour Measurement” by Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A.,
Moussa M., Cool, D., Romagnoli, C., Bauman G. and Ward A., to SPIE Journal of
Medical Imaging, 2014 (in preparation).
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1.6.2 Chapter 3: Evaluation of accuracy, inter-observer variability, and
inter-sequence variability of tumour burden on multi-parametric
MRI
Prostate tumour volume measurement can inform prognosis and treatment selection,
including an assessment of the suitability and feasibility of focal therapy. MPMRI is
showing promise for prostate cancer detection. We investigated the accuracy, interobserver variability, and inter-sequence variability of tumour volume estimation via
separate contouring of 3-Tesla T2W, DCE, and ADC images using a histologic reference
standard. This chapter addresses objectives 5 and 6 as described in Section 1.5.
A version of this chapter has been published as “Accuracy and variability of tumour
burden on multi-parametric MRI,” by M. Salarian, M. Shahedi, E. Gibson, M. Gaed, J.A.
Gomez, M. Moussa, G.S. Bauman, A.D. Ward, in the proceedings of SPIE Medical
Imaging 2014.

1.6.3 Chapter 4: Summary and conclusion
This chapter summarizes the overall contributions and conclusions of this thesis.

1.6.4 Chapter 5: Future work
This chapter outlines some potentially productive areas of future work arising
from this thesis.
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Chapter 2
2

Toward quantitative digital histopathology for
prostate

cancer:

comparison

of

inter-slide

interpolation methods for tumour measurement
2.1

Introduction
Prostate cancer (PCa) is the most common non-cutaneous cancer among men,

with hundreds of thousands of diagnoses and tens of thousands of deaths annually [1]. In
2012, it was the second leading cause of cancer death among North American men, with
an estimated 268,240 diagnoses and 32,170 deaths [2]. Approximately 40% of men with
organ-confined PCa undergo radical prostatectomy (surgical removal of the entire
prostate), with nearly 80,000 surgeries per year in the United States [3]. After surgery,
about 35% of patients have subsequent biochemical failure (BCF) [4], which is measured
by an increase in prostate-specific antigen (PSA) in the blood, with increased risk of
metastatic cancer and death [5]. After BCF, it may be possible to cure the patient by
applying follow-up curative-intent androgen deprivation [6], or prostate bed irradiation
[7] to destroy any remaining cancer. Pre-emptive (adjuvant) follow-up therapy has been
shown in clinical trials to improve cancer control and reduce BCF [7]. However, the
clinical decision of whether to apply adjuvant therapy is important and challenging.
Adjuvant therapy cannot be used for all patients due to the serious side effects that can
occur, but can be life-saving for appropriate patients. Identification of prostatectomy
patients who are at elevated risk of biochemical failure and would benefit from postprostatectomy adjuvant therapy is therefore critical to PCa control and cure.
The pathologist's assessment of the removed prostate is very important to this
clinical decision [8]. Traditional surgical pathology assessment of prostatectomy
specimens includes tissue fixation in buffered formalin for 12–48 hours followed by
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slicing into 3–5 mm thick tissue sections which are subsequently embedded in paraffin
blocks. Tissue sections 4–5 µm in thickness are then cut with a microtome from each
block face for hæmatoxylin and eosin (H&E) staining. The pathologist then conducts a
microscopic examination of the sections. Each tumour is assessed in several ways,
including (but not limited to) location within the prostate, volume assessment and degree
of differentiation (the latter using the Gleason grading system [9]). The determination of
whether a patient is a candidate for adjuvant therapy depends in part on prognostic
information derived from the total volumes and Gleason grades of the tumours assessed
on the resected specimen [8].
Tumour volume assessment in the radical prostatectomy specimen is particularly
challenging to report quantitatively, and substantial variability has been reported in the
volume estimation methods used clinically [10, 11]. The ongoing transition to digital
pathology has been fostered by high-resolution whole-slide scanners and opens the
possibility for the integration of computational tools into the digital pathology workflow
in order to enable quantitative assessments and reporting in a clinically feasible fashion.
The emergence of automatic techniques for prostate cancer detection and localization on
2D digital pathology imaging [12-14] provides an opportunity for computer-assisted
tumour quantification. However, clinicians interpreting pathology reports require an
understanding of the 3D tumour burden when making treatment decisions. One important
challenge to 3D tumour volume quantification is the sparse sampling of the prostate
tissue performed during the usual clinical pathology protocol [15]. For reasons of
practicality and cost, 4 µm tissue sections are typically obtained at 3–5 mm intervals for
mounting on microscope slides (this interval is henceforth referred to as inter-slide
spacing) for clinical prostate specimens. Thus, in 3D, digital pathology imaging of
clinical prostate specimens contains much denser information within each slide (often
0.25–0.50 µm pixels), relative to the information obtained in the through-slide direction.
In the current absence of widespread clinical implementation of whole slide
scanning and automated tumour delineation, there are several simpler approximations to
prostate tumour volume measurement that have been used clinically and in the research
setting. Examples include measurement of the diameter of the largest tumour focus,
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assessment of maximum tumour area using a single or multiple slide approach, counting
of the number of involved blocks, assessment of the positive to negative block ratio, use
of a measuring grid, and point counting [16, 17]. To evaluate these approaches, a
planimetric method has been used in several studies as a reference standard for estimating
tumour volume on digital pathology of the prostate [16, 18, 19]. In this method, each
tumour is contoured on each slide, and tumour volume is calculated by multiplying the
estimated within-slide tumour area by the inter-slide spacing. This approach will
henceforth be referred to as the nearest-neighbour (NN) interpolation method, since the
tumour shape on any parallel plane between two sections is estimated to be the same as
the tumour shape on its nearest neigbouring section. This method has the advantage of
being relatively straightforward from a computational standpoint. However, due to the
large difference between the slice thickness (4–5 µm) and slide spacing (3–5 mm), this
approach can produce sharp changes in the tumour surface along the direction orthogonal
to the slides, bringing the biological plausibility of the 3D interpolation into question.
This concern may be mitigated by a through-slide tumour boundary interpolation method
designed to produce smooth tumour surfaces. In this work, we implemented and tested a
level set (LS)-based interpolation scheme for this purpose, on which we provided a
preliminary report in a conference proceedings [20]. This chapter extends our previous
work in several important ways. Specifically, in this chapter, we measured the accuracy
of the LS method for tumour boundary interpolation in comparison to the NN method,
and measured the suitability of simpler tumour volume estimation techniques as
surrogates for the tumour volumes calculated from the smooth tumour surfaces given by
the LS method. As a secondary question, we examined the effect of modifying inter-slide
spacing on the variability of tumour volume estimates, as this can inform optimization of
pathology protocols for reproducibility of tumour volume estimation. With the clinical
transition to whole-slide digitization and automated analysis on the horizon, the
knowledge generated by this work can inform the choice of tumour volume measurement
approach that provides the most appropriate balance of accuracy versus efficiency in the
clinical pathology environment.
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2.2

Materials and Methods

2.2.1 Materials
In this study, we acquired images from two different cohorts of patients, to
support the evaluation of our tested tumour volume measurement methods in two ways.
Both cohorts are part of clinical trials currently underway at our centre, both approved by
the human subject research ethics board of our institution with written informed consent
obtained from all patients. One cohort is a set of radical prostatectomy patients for whom
we have 2D tumour contours on post-prostatectomy histology. The other cohort is a set of
patients who underwent magnetic resonance imaging (MRI)-targeted, 3D transrectal
ultrasound-guided “fusion” prostate biopsy, for whom we have 3D tumour contours on
pre-biopsy MRI. The specific details of each cohort are described in the following
subsections.

2.2.1.1

Radical prostatectomy patients

Twenty-one patients with biopsy-proven prostate cancer who underwent radical
prostatectomy between June, 2010 and December, 2011 were recruited by three
collaborating urologists/surgical oncologists. The inclusion criteria were: (1) age 18 years
or older, (2) clinical stage T1 or T2 prostate cancer histologically confirmed by biopsy,
and (3) suitable for and consenting to radical prostatectomy. The exclusion criteria were:
(1) prior therapy for prostate cancer, (2) use of 5-alpha reductase inhibitors within 6
months of the study start, (3) inability to comply with preoperative imaging, (4) allergy to
contrast agents, (5) sickle cell or other anemias, (6) hip prosthesis, (7) sources of artifact
within the pelvis, and (8) contraindications to MRI.
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Figure 2.1. Block diagram describing the data acquisition and pre-processing from our
radical prostatectomy patients.
The schematic in Figure 2.1 provides a high level description of the data
acquisition and pre-processing we performed for the radical prostatectomy patients. The
details from radical prostatectomy up to and including image preprocessing are as
follows. For each patient, after radical prostatectomy, the resected prostate was fixed in
10% buffered formalin for 48 hours. Each specimen was then transversely sliced into 4.4
mm thick tissue slices, which were paraffin-embedded. A single 4 µm-thick whole-mount
hæmatoxylin and eosin-stained tissue section was taken from each block face and
mounted on a positively-charged glass slide. The slides were digitized using a ScanScope
GL (Aperio Technologies, Vista, CA, USA) bright field slide scanner. The acquired
images were 24-bit colour with isotropic 0.5 µm2 pixels. From each patient, between 3
and 5 (median 4) whole-mount sections were obtained; 82 such sections were obtained in
total. For each specimen, adjacent section images were aligned using orientation
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information derived from our previously developed method for 3D histology
reconstruction [21].
An experienced clinician contoured and graded all lesions on each histology
image using the ScanScope ImageScope v11.0.2.725 software (Aperio Technologies,
Vista, CA, USA) and a Cintiq pen-enabled display (Wacom Co. Ltd., Saitama, Japan);
these contours were reviewed and edited as necessary by one of two genitourinary
pathologists. We designated all tumour areas containing any Gleason grade 4 or 5 as
high-grade; all other tumours were designated as low-grade. Figure 2.2 shows an
illustrative example of this contouring; note the variability of tumour shapes in Figure
2.2(a-d). Contouring was performed at high magnification (i.e. using the 20×
magnification setting in the ImageScope software (Figure 2.2(f)), rendering 0.5 µm × 0.5
µm pixels). Figure 2.2(e) and (f) provide an illustration of the attention to detail applied
to this contouring task. From these contours, we extracted a total of 144 tumours, 110 of
which were low-grade (from all 21 patients) and 34 of which were high-grade (from 16
patients). 126 tumours spanned a single microscope slide, 14 tumours spanned 2 slides, 3
tumours spanned 3 slides, and 1 tumour spanned 4 slides. For improved processing speed
and to close small gaps introduced by the meticulous contouring (Figure 2.2(f)), each
slide was rasterized to a 0.25 mm × 0.25 mm pixel binary image and thresholded at 0.5
after preprocessing using a 1 mm-radius disk-shaped averaging filter.

Figure 2.2. (a-d) Sample contoured whole-mount histopathology images. (e) and (f) are
zoomed from the large and small boxes in (d), respectively. Colour code is as follows.
Brown: low-grade cancer. Gray, dark green, purple: regions containing several different
grades of cancer, all including some high-grade cancer. Cyan: extraprostatic extension of
tumour. Blue: atrophy (benign). Light green: prostatic intraepithelial neoplasia (benign).
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2.2.1.2

MRI-targeted fusion biopsy patients

Fourteen patients underwent prostate MPMRI using a Discovery MR750 (GE
Healthcare, Waukesha, WI, USA) at 3T using T2W, T1-weighted dynamic contrastenhanced, and diffusion-weighted sequences (sequence parameters shown in Table 2.1).
Pelvic phased array and endorectal receive coils were used simultaneously for these
acquisitions. The schematic in Figure 2.3 provides a high level description of the data
acquisition and pre-processing we performed for the radical prostatectomy patients. After
MPMRI acquisition, a radiologist and radiology resident, each with > 5 years of
experience reading > 200 prostate MRI cases, assessed the multi-parametric MRI using
guidelines concordant with the prostate imaging and reporting data system (PI-RADS)
[12] and delineated a total of 24 3D tumour volumes on the MRI. All three sequences
were used to identify tumours (as in the PI-RADS guidelines), and the tumours were
contoured in the coordinate system of the T2W images. These contours were performed
using custom software that allowed the operator to manipulate control points defining a
3D tumour surface with subvoxel precision. This approach mitigates segmentation
precision issues arising due to the thickness of the MR image planes. This yielded 14 3D
label maps in the T2W coordinate system, one for each patient, depicting a total of 24
contoured tumour regions. For each of the 3D contoured tumours, we calculated tumour
volume by multiplying the number of voxels within each region by the voxel size in mm3.
Table 2.1. MRI sequence parameters.
Sequence
Repetition time (msec)

T2W
4833

DCE
3.1

DW
4000

Echo time (msec)
Bandwidth (kHz)
Number of excitations
Field of view (cm)
Slice thickness (mm)
Slice spacing (mm)
Matrix
Number of slices
Flip angle (°)
Temporal spacing (s)
B-value

160
31.25
4
14
2.2
0
320 × 192
30-40
90
N/A
N/A

1.5
83.33
1
14
3.0
0
128 × 128
32
12
6-7
N/A

70–77
166.7
3
14
3.6
0
128 × 256
20–34
90
N/A
100, 800
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Figure 2.3. Block diagram describing the data acquisition and pre-processing from our
fusion biopsy patients.

2.3

Methods
In this section, we describe the level set-based tumour interpolation method we

developed, a set of conventional methods that have been previously reported in the
literature, and our approaches to measurement of tumour volume accuracy. All data
processing in this work was performed using custom software written in Matlab 7.12.0
(The Mathworks, Inc., Natick, MA, USA).

2.3.1 Level set-based interpolation method for tumour volume
estimation
We implemented an approach to shape interpolation that is based on the level set
representation (as distinct from the often-reported use of the level set representation for
image segmentation) [22]. Our rationale for the use of a level set based approach is based
on our observation that histologic tumour shapes are complex and can change in topology
from one slide to the next (e.g. a 3D tumour can appear as a single connected 2D
component on one slide and multiple disconnected 2D components on an adjacent slide).
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The level set representation is ideally suited for such shape interpolation problems. The
level set implicitly represents shape boundaries using a signed distance map defined
everywhere in the image domain, where zero crossings define the shape boundaries.
Through-slide interpolation of these signed distance values produces a smooth evolution
of complex boundary shapes from one slide to the next.

Figure 2.4. Block diagram describing the steps involved in the level set-based
interpolation method.
Figure 2.4 provides a schematic showing the steps of our LS-based shape
interpolation method. On each slide, we represent the tumour cross section as a 2D binary
image, with pixels covering an area of 0.25 mm × 0.25 mm. For each such image
, : ℤ → 0,1 a level set representation

 , : ℤ → ℝ was calculated by

computing the signed distance transformation of the shape boundary. To interpolate
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tumour shapes between slides having an inter-slide spacing of  mm ( = 4.4 in our
study), pixel correspondence was established according to , , and corresponding level
set values  ,  were interpolated in increments of  mm in the through-slide direction
using a cubic spline. In our study, we set  to 0.2 mm; thus, our tumours were
interpolated in a 3D coordinate system with 0.25 mm × 0.25 mm × 0.2 mm voxel size. To
avoid flat “caps” of the tumours at the first and last slides, we defined extrapolated level
sets at /2 mm from each cap via level set evolution using speed a function that was
constant throughout the domain , . The constant was chosen such that the evolving
level set would cause the shape to vanish at 

, /2 mm from the first and last slides

of the tumour, where  was defined as  !  , . This choice of speed function
encourages 3D isotropy of one-slice tumours and guarantees that tumours will not be
extrapolated into regions where they are known not to exist (based on their absence from
adjacent contoured slides). The extrapolated level sets were incorporated into the spline
interpolation as described above. Thus, 1-slide tumours were interpolated using 3 level
sets, 2-slide tumours using 4 level sets, etc. After interpolation, the final 3D shapes were
defined by thresholding the interpolated level sets at 0, yielding a 3D binary image
containing each tumour. Tumour volume was calculated as the number of voxels within
the tumour region multiplied by the voxel size.

2.3.2 Conventional tumour size estimation methods
To compare the LS-based volume estimation approach with previously-defined
approaches, we performed several tumour volume estimation calculations as described in
[16, 19] and enumerated as follows. (1) In the nearest-neighbour (NN) planimetric
approach, tumour volume was calculated by multiplying the area within each contoured
tumour on each slide by the inter-slide spacing, and summing these areas for tumours
appearing on multiple slides. Thus, this approach requires that the entire tumour be
outlined on every slide on which it appears. (2) In the maximum tumour diameter (MTD)
approach, tumour size was estimated as the length of the longest chord within the tumour
on any of the slides on which it appeared. Thus, this method is considerably less labourintensive, requiring only that the pathologist find the slide containing the largest tumour
cross section and take a single linear measurement. (3) In the estimated square area
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(ESA) approach, tumour size is estimated by multiplying the MTD by the length of the
longest chord perpendicular to the chord used to calculate MTD; effectively this is the
area of a bounding box of the largest tumour cross section. This method is also much less
labour intensive than the NN approach, requiring only two linear measurements on a
single slide. (4) In the cubic volume (CV) approach, tumour volume was estimated as the
product of ESA and the total cross-sectional thickness of the tumour (i.e. the number of
slides on which the tumour appeared, multiplied by the inter-slide spacing).

2.3.3 Tumour volume accuracy measurement and comparison
An ideal means for measuring the accuracy of 3D tumour volume measurement
on histology would be to perform a complete serial step sectioning of the prostate tissue,
perform expert manual contouring of the tumours on each section, and calculate tumour
volume as the sum of cross sectional tumour areas, multiplied by the section thickness
(e.g. 4 µm). However, this approach is impractical for two primary reasons. First, for a
prostate measuring 4 cm in the inferior-superior direction orthogonal to the plane of
sectioning (a typical size of a radical prostatectomy specimen), complete serial sectioning
at 4 µm would yield 10,000 sections to be mounted on slides, stained, coverslipped,
scanned, and processed. This is clearly a cost-prohibitive process to perform for any
reasonable number of specimens in a study, and to the best of our knowledge, only a
single specimen has been processed in a similar fashion and reported in the literature
[23]. Second, clinical pathology departments require that most of the tissue from radical
prostatectomy specimens be retained in paraffin blocks to aid in diagnosis of future
malignancies in the patient. Consequently, from clinical specimens, one obtains a thin
tissue section at widely spaced intervals throughout the prostate (typically 3–5 mm in
clinical practice); in our study, we obtained a section every 4.4 mm. Thus, practical and
cost considerations aside, regulations dictate that complete serial sectioning of prostates
could be performed only on autopsy specimens, where inclusion and exclusion criteria
may be more challenging to measure. Thus, surrogates for this ideal reference standard
for histologic tumour volume are valuable to the evaluation of tumour volume estimation
algorithms.
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We used two different reference standards to evaluate the LS and NN
interpolation methods. Our first reference standard is the set of 3D tumour shapes
contoured on multiparametric MRI from our fusion biopsy cohort. We simulated
histologic sectioning of these shapes by extracting 2D cross sections at specified spacing,
and then measured the accuracy of the different interpolation methods in reconstructing
the original 3D shapes. This reference standard has the advantage of being inherently 3D,
but has the disadvantage of consisting of a set of shapes that are not directly derived from
a histologic assessment of the tumours. The shapes are indirectly measured on MRI and
thus we consider them to be plausible, not actual, tumour shapes. As a complementary
approach to address this issue, our second reference standard is the set of 2D tumour
contours on histology images from our radical prostatectomy cohort. To test the
interpolation methods using this reference standard, we drop one dimension from the
interpolation calculations. That is, rather than interpolating 2D cross sections to a 3D
shape, we use the same interpolation methods to interpolate 1D cross sections a 2D
shape; we can then use the 2D histologic contours as a reference standard. Although this
reference standard has the disadvantage of being intrinsically 2D, it has the advantage of
being measured directly from the histologic images, consisting of actual tumour shapes,
and is thus complementary to our MRI-based reference standard.
We tested the performance of the tumour size estimation methods under idealized
tumour slicing conditions, where the set of slices were centered within the tumour, and
the distance between the outermost slices and the true tumour edges was known (Figure
2.5(a)). This idealized arrangement is not generally obtained in practice, but serves as a
means for a baseline comparison of the best-case performances of the methods. More
specifically, our assumption was that the tumours were cut with a " mm spacing (we used
" = 4.4 mm, as this is the spacing used in our radical prostatectomy cohort) between
slides, and that the distance # (mm) between the outermost slides and the ends of the
tumour were known. This is described in the diagram in Figure 2.5(a). As a further
illustration in the context of the 3D MRI-based reference standard, consider a tumour
with length $ mm (henceforth taken to be the tumour size measured in the direction
orthogonal to the slides) less than " mm. To provide the interpolation algorithms with a
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simulated histologic tumour cross section, a cross sectional slice from the MRI must be
selected. In this idealized experiment, the selected slice was at the midpoint between the
tumour extents, and # = $/2 mm. For a tumour with L > T, s > 1 MRI slices were
selected such that the outermost slices are equidistant from the ends of the tumour, and
# = $ – " ×  − 1/2 mm. For the 2D histology-based reference standard, the
calculations were the same, except that rather than extracting 2D cross sections from the
3D contoured MR images, instead we extracted 1D cross sections from the 2D contoured
histology images.

2.3.4 Assessment of impact of inter-slide spacing on variability of
tumour volume estimation
Since tumour volume on histology must be measured using sparsely sampled 2D
histology sections, the estimated volume depends in part on the spatial locations where
the cuts are made in the specimen to take the sections. Thus, the estimated volume may
vary as a function of the positioning of these cuts; this variability may be mitigated by
taking a larger number of more closely-spaced sections. The choice of inter-slide spacing
involves a compromise between the benefits of increased sampling of the specimen
(smaller spacing), and benefits of reduced time and costs with fewer slides (larger
spacing). Using our MRI-based 3D reference standard, we measured the effect of varying
inter-slide spacing on volume estimation by computer simulation. We simulated slicing at
all possible knife blade positions within the specimen (quantized to 0.2 mm steps) with
the inter-slide spacing values ranging from 2 mm to 6 mm, in 1 mm increments. For each
spacing, we measured the standard deviation of the tumour volume estimates across all
blade positions, for both the LS and NN methods.
To assess the impact of inter-slide spacing on variability of tumour volume
estimation, we fully relaxed the assumption of ideal slicing, and simulated all possible
spatial arrangements of slices within the tumour (Figure 2.5(b)). This experiment
provides results closer to what would be expected if the methods were put into use in a
clinical environment, where the tumours within the prostate are not visible to the
histotechnologist during the slicing process, and therefore the histotechnologist has no
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means of controlling the slicing for optimal sampling of the tumours. More specifically,
this experiment relaxed the assumption of ideal tumour slicing by testing the interpolation
approaches through all possible slicing configurations (quantized to 0.2 mm steps). In
addition, knowledge of the tumour extents beyond the outermost slices was not assumed;
the locations of these extents were estimated to be "/2 mm beyond the outermost slices.
This is described in the diagram in Figure 2.5(b). As a further illustration in the context of
the 3D MRI-based reference standard, consider a tumour with length $ < " mm. To
provide the interpolation algorithms with a simulated histologic tumour cross section, a
cross sectional slice from the MRI must be selected. In this experiment, we repeated the
interpolation for every cross sectional slice, in 0.2 mm increments, throughout the length
of the tumour. For a tumour with L > T, s > 1 MRI slices were selected repeatedly for
every possible positioning of such evenly spaced slices (" mm spacing) within the
tumour. In all cases, the surface was extrapolated to "/2 mm extents on either side of the
outermost extracted slice(s). For the 2D histology-based reference standard, the
calculations were the same, except that rather than extracting 2D cross sections from the
3D contoured MR images, instead we extracted 1D cross sections from the 2D contoured
histology images.

Figure 2.5. (a) Depiction of slice positions and extrapolation regions for experiments
simulating idealized slicing. (b) Depiction of slice positions and extrapolation regions for
experiments simulating realistic slicing. For clarity, only four possible slicing
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configurations are shown (black, green, purple, and yellow) but in the experiments, all
possible slicing configurations are used.

Figure 2.6. 3D surface renderings of interpolated tumours for three patients (one per
column), under idealized tumour slicing assumptions. Low grade tumours are in blue and
high grade tumours are in red. Top row: NN interpolation approach. Bottom row: LSbased interpolation approach.

2.4

Results

2.4.1 Tumour volume accuracy measurement and comparison
Figure 2.6 illustrates qualitative results of 3D tumour shape interpolation for 3
patients, showing 3D surface renderings of interpolated tumours using the NN
interpolation and LS-based interpolation approaches using 3D Slicer version 3.6
(Surgical Planning Lab, Harvard Medical School, Boston, USA) [24]. Low-grade
tumours are shown in blue and high-grade tumours are shown in red. Notable is the
increased plausibility of the 3D tumour shapes produced via the LS-based interpolation
approach. These 3D interpolations are comparable to our MRI-based reference standard
for accuracy assessment. Figure 2.7 provides a similar illustration of the qualitative
results in 2D, which are comparable to our histology-based reference standard for
accuracy assessment. In this figure, the true histologic boundaries are shown overlaid
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with the interpolated boundaries; note the superior agreement of the LS-based boundaries
to the reference boundaries.

Figure 2.7. 2D boundaries of interpolated tumours for two patients (one per
column), with the true boundaries from the contoured histology in green and the
interpolated boundaries in blue, under idealized tumour slicing assumptions. The
dashed lines show the 1D sampling regions from which the interpolations were
performed. Top row: NN interpolation approach. Bottom row: LS-based
interpolation approach.
Table 2.2 shows descriptive statistics for the volume estimates given by the NN
and LS approaches, with breakdown according to high-grade vs. low-grade tumours, and
breakdown according to whether the tumours occupied a single slide (i.e. cases where
$ < ") vs. cases where the tumours occupied more than one slide. We performed one-
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sample Kolmogorov-Smirnov normality tests of the tumour volumes computed using the
two methods. Our data did not pass the normality tests, necessitating the use of nonparametric hypothesis tests. We used both the Wilcoxon sign rank test and the MannWhitney U-test to test the null hypothesis that the median volume measured by the NN
method was the same as that measured by the LS method. The null hypothesis was
rejected by both tests (p < 0.001). Thus, the NN interpolation approach produces a larger
tumour volume compared to the LS-based interpolation approach by a median factor of
2.3 overall.

Table 2.2. Descriptive statistics of tumour volumes estimated based on histologic tumour
contours by the NN and LS methods for the radical prostatectomy patients.
Tumours
All
Low-grade
High-grade
1-slide
>1-slide

Interpolation
NN
LS
NN
LS
NN
LS
NN
LS
NN
LS

Tumour volume (mm3)
Std. dev.
Median
81.2
13.2
65.5
5.7
59.4
14.1
47.4
6.1
141.7
12.4
115
5.3
24.2
13.2
14.5
5.6
194
111.4
159.9
89.6

Mean
38.1
23.9
37.7
23.2
40.1
26.8
21.8
10.5
174.9
135.7

IQR
15.6
7.5
22.1
11.1
2.2
1.1
8.8
3.9
152.1
123.3

The scatter plots in Figure 2.8 depict the relationships between the volumes
measured using the NN and LS approaches, for the radical prostatectomy patients and the
fusion biopsy patients. For the radical prostatectomy patients (Figure 2.8(a)), we found
different linear relationships between the volumes for 1-slide tumours (blue points) and
>1-slide tumours (red points), with correlation coefficient  = 0.99 for both. We used
linear regression ($+ ,- . =

// ,- . + 1) to elucidate the relationships; the

coefficients are shown in the tables within the figure. After using these linear models to
adjust the NN-based volumes, the Bland-Altman plots in Figure 2.9 depict the residual
differences between the two methods. These plots indicate negligible bias, with tighter
limits of agreement for the radical prostatectomy cohort.
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This suggests that the

difference in volume estimates for the two methods is larger for larger tumours, as seen in
the fusion biopsy cohort.
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Figure 2.8. Comparison of volumes estimated using the NN and LS-based interpolation
methods on (a) the radical prostatectomy patients and (b) the fusion biopsy patients,
under idealized tumour slicing assumptions. Blue points: 1-slide tumours. Red points: >1slide tumours. For clarity of interpretation, two high-volume outliers (high-grade tumours
with level set volumes of 480 mm3 and 824 mm3) were omitted from (a).
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Figure 2.9. Bland-Altman plots for (a) the radical prostatectomy patients and (b) the
fusion biopsy patients, under idealized tumour slicing assumptions. For clarity of
interpretation, two high-volume outliers (high-grade tumours with level set volumes of
480 mm3 and 824 mm3) were omitted from (a).
The scatter plots in Figure 2.10 depict the relationships between the tumour sizes
measured using the simpler MTD, ESA, and CV approaches, and the NN and LS
approaches. For the relationships involving cubic volume, a linear regression was used,
with coefficients shown in the tables within the figures. As MTD and ESA are measured
in mm and mm2 units, respectively, their relationships to the NN and LS tumour volumes
measured in mm3 units were elucidated by fitting cubic and quadratic polynomials,
respectively, with coefficients shown. The cubic polynomial has the form $+ ,- . =
× // ,- .2 + 1 × // ,- .  + 3 × // ,- . + .
quadratic polynomial has the form $+ ,- . =

The

× // ,- . + 1 ×

// ,- . + 3. The scatter plots and coefficients indicate that different
relationships exist for 1-slide and >1-slide tumours. After using these models to adjust
the MTD, ESA, and CV-based size estimates, the Bland-Altman plots in Figure 2.11
depict the residual differences between these methods and the NN and LS-based
methods. One can observe that the relationships between the tumour sizes estimated
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using the simpler approaches and the LS and NN approaches are similar, and the limits of
agreement become smaller as one moves from the one-dimensional MTD size estimate to
the two- and three-dimensional ESA and CV approaches.
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Figure 2.10. Scatter plots showing the relationship between the MTD (first row), ESA
(second row), and CV (third row) tumour size estimation methods and the tumour
volumes obtained from the NN approach (first column) and the LS approach (second
column), under idealized tumour slicing assumptions. Blue points represent 1-slide
tumours, and red points represent >1-slide tumours. For clarity of interpretation, two
high-volume outliers (high-grade tumours with level set volumes of 480 mm3 and 824
mm3) were omitted from all graphs.
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Figure 2.11. Bland-Altman plots of adjusted MTD (first row), ESA (second row), and
CV (third row) tumour size estimation methods and the tumour volumes obtained from
the NN approach (first column) and the LS approach (second column), under idealized
tumour slicing assumptions. For clarity of interpretation, two high-volume outliers (highgrade tumours with level set volumes of 480 mm3 and 824 mm3) were omitted from all
graphs.
Figure 2.12 shows histograms of the accuracy measurements of the NN and LS
methods with respect to the MRI-determined tumour volumes on our fusion biopsy
cohort, with the mean and standard deviation of the errors shown. Figure 2.13 shows
Bland-Altman plots for the same data as shown in Figure 2.12. Analogous histograms to
Figure 2.12 are shown in Figure 2.14 using the histology-determined 2D tumour areas
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from our radical prostatectomy cohort, with corresponding Bland-Altman plots in Figure
2.15. Overall, these plots indicate that both the NN and LS methods are biased toward
underestimating tumour size, as compared with reference standard tumour sizes on MRI
and histology. However, the limits of agreement for the LS method are tighter, as
compared to the limits of agreement for the NN method, as shown in Figures 2.13 and
2.15.
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standard tumour volumes.
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15

Bland-Altman: LS vs. histology

15

10

10
LS – histology (mm2)

NN – histology (mm2)

Mean + 2*SD

5
0
-5
-10

20

Mean + 2*SD

0
-5
-10 Mean - 2*SD

Mean - 2*SD

-15
0

5

40

60

80

100
2

-15
0

20

40

60

80

100

Average of LS and histology (mm2)

Average of NNand histology (mm )

Figure 2.15. Bland-Altman plots of average and difference in NN-based areas (left) and
LS-based areas (right) with respect to the 2D histology-defined reference standard
tumour areas.

2.4.2 Assessment of impact of inter-slide spacing on variability of
tumour volume estimation
We measured the variability of tumour volumes estimated using the NN and LSbased interpolation approaches as a function of inter-slide spacing. Figure 2.16 shows the
standard deviations of the volumes reconstructed using NN and LS-based interpolation
approaches versus inter-slide spacing values of 2, 3, 4, 5 and 6 mm. It is apparent on this
figure that the variability of tumour volume estimates increases with increasing interslide spacing.
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Figure 2.16. Tumour volume estimated via NN-based (blue) and LS-based (red)
interpolation methods vs. inter-slide spacing of 2, 3, 4, 5 and 6.

2.5

Discussion
Several studies [25-29] have shown that the tumour volume measurement is an

independent prognostic indicator that can predict the development of metastases,
extraprostatic extension of the tumour, as well as overall survival in PCa patients.
However, other studies have shown contradictory results [30-32]. These conflicting
results could be attributed to the use of different tumour volume estimation approaches in
the different studies, and use of methods which are subject to observer variability.
Consequently, it has been suggested to utilize new technologies such as whole-slide
digital histology imaging to support the repeatable measurement of tumour volume and
address these issues [10].
An accurate and repeatable histologic tumour volume reference standard is
valuable to studies validating imaging for appropriate treatment selection and guidance.
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Radical prostatectomy, radiation therapy, cryotherapy, or high-intensity focused
ultrasound (HIFU) can be used for whole-gland treatment of organ-confined prostate
cancer. These treatments have frequent urinary, rectal, and sexual side effects. Although
active surveillance may be an option for some patients, patients who fail active
surveillance frequently subsequently receive conventional whole-gland treatment [33].
As a compromise between the extrema of radical therapy and active surveillance, focal
therapy, or subtotal ablation, can be appropriate for patients with low-risk cancer
characteristics, and is a technique that could allow the physician to eradicate all known
foci of prostate cancer while minimizing damage to adjacent structures [34]. Focal
therapy involves intensely treating the portion of the gland that contains significant
tumour. This targeted treatment strategy has the potential to preserve the normal tissue
and reduce the resultant side effects that are associated with removal or destruction of the
entire prostate gland [35]. Focal therapy can be performed using several techniques,
including thermo-ablative methods, using either heat or cold to destroy tumours, such as
interstitial laser therapy, cryoablation and HIFU; radiation methods, such as
brachytherapy; or chemical methods, such as regional alcohol injection [34]. Image–
guided focal therapy depends on the validation of imaging modalities for detection and
localization of cancer, and patient selection depends in part on tumour location and
volume. Therefore, with the development of focal therapy, tumour burden assessment on
imaging is becoming more valuable and a reliable histologic tumour volume reference
standard is required for imaging validation studies [36].
In this work, we have developed a LS-based through-slide interpolation technique
for estimating prostate tumour volume on digital histopathology images which produces
smoother, potentially more plausible tumour shapes compared to a typically used NNbased technique. Our quantitative results show that using the LS-based technique, on
average, estimates a lower tumour volume compared to the NN-based approach for both
low-grade and high-grade tumours. It has been observed that the volumes calculated via
the NN interpolation approach, which requires less sophisticated software for calculation,
can be linearly adjusted to match those calculated via the LS-based interpolation
approach. This suggests that for studies where the volume is the only measure of interest
of the tumour, the NN-based technique may be sufficient. However, for imaging
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validation studies where the precise tumour boundary location is of interest, the smooth
boundaries produced by the LS technique may be a more plausible reference standard.
We observed that for the simpler tumour size estimation approaches (MTD, ESA,
and CV), stronger relationships were found between the ESA and CV measures and the
NN and LS measures, compared to the linear relationships found between the MTD and
NN and LS measures. The MTD, ESA, and CV measures are 1-, 2-, and 3-dimensional,
respectively. Our results suggest that the 1-dimensional MTD measurement, although
straightforward to implement in a clinical pathology workflow, suffers from a relatively
poorer relationship to tumour volume, as compared to the 2- and 3-dimensional
approaches. If one is to resort to one of these more straightforward approaches, it would
be worthwhile to use the ESA method at minimum; fortunately, the ESA can be
calculated straightforwardly with only one additional measurement taken on the same
slide on which the MTD is measured, so the incremental time cost of using the ESA
method over the MTD method is likely to be small.
We observed a small difference in accuracy of the LS and NN tumour volume
estimation approaches, with the LS approach yielding a slightly greater underestimation
with respect to the MRI and histology-based reference standards. The LS method
demonstrated less variability in error, suggesting that it is possibly less sensitive to
variability in tumour shape.
Our data in Figure 2.16 indicate that there is a compromise between the variability
of tumour volume estimation and inter-slide spacing; larger inter-slide spacing increases
the variability of tumour volume estimation. However, decreasing the inter-slide spacing
leads to an increase in the number of the digital histopathology slides and increases the
cost of processing. Furthermore, inter-slide spacing values of less than 3 mm have been
observed to cause tissue to warp excessively, rendering paraffin embedding challenging;
3 mm may be a practical lower limit for inter-slide spacing in a clinical pathology
context. Our data suggest a rapid increase in variability of tumour volume estimation as
inter-slide spacing rises beyond 5 mm. Overall, these data reinforce the current clinical
standard approach of taking a slide every 3–5 mm, and support a decision to use a slide
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spacing at the low end of this range for studies where precision of tumour volume
estimation is important.
The results of our work need to be considered in the context of its assumptions
and limitations. Because of a lack of ground truth contours between slides, evaluation of
an interpolation approach is challenging; we resorted to using an MRI-based 3D
reference standard, and performing our analysis in a reduced 2D space in order to
evaluate the approach’s ability to interpolate sparsely sampled 2D histology contours.
Also, our current approach assumes that after 3D reconstruction, all histology slides are
parallel, which is generally not the case due to variability in tissue cutting. Our ongoing
work is intended to address both of these challenges.
In conclusion, level set-based through-slide interpolation of prostate tumours on
digital pathology produces smoother 3D tumour surfaces that may be more biologically
plausible than those produced via a typically used simpler nearest-neighbour
interpolation. For cases where only tumour volume is of interest, the volumes produced
via the simpler approach can be linearly adjusted to the level set-produced volumes, and
the accuracies of volume estimation of the two approaches were similar. The smoother
surfaces yielded by level set interpolation may be valuable to pathology-based imaging
validation studies where tumour boundary location is important. In clinical scenarios
where tumour contouring is impractical, volumes can be estimated based on 1-, 2-, or 3dimensional tumour size measurements, with the 2-dimensional estimated square area on
the largest histologic tumour cross section yielding a good compromise between
efficiency and direct relationship to tumour volume estimated using planimetric
approaches. Variability in histologic tumour volume estimation was found to increase
with larger inter-slide spacing; for studies requiring the greatest repeatability of
measurements of tumour volume, an inter-slide spacing of 3 mm is recommended.
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Chapter 3
3

Accuracy and variability of tumour burden
measurement on multi-parametric MRI

3.1

Introduction
Early detection and accurate preoperative assessment of prostate cancer are

crucial to the selection of appropriate treatment [1]. The combination of digital rectal
examination (DRE), prostate-specific antigen (PSA) testing, and 2D transrectal
ultrasound (TRUS)-guided biopsy has resulted in enhanced screening and diagnosis of
prostate cancer, detecting smaller tumours at an earlier stage [2]. However, due in part to
the high sensitivity and low specificity of screening, prostate cancer is currently overdiagnosed [3], potentially leading to unnecessary patient anxiety, diagnostic
interventions, and aggressive whole-gland treatment (radiotherapy or prostatectomy
surgery) with associated side effects. Approximately 40% of men with organ-confined
PCa undergo radical prostatectomy, with nearly 80,000 surgeries each year in the United
States [4]. Consequently, there is an increasing interest in the use of focal therapy for
intermediate-risk cancers to treat localized prostate cancer while minimizing damage to
the healthy tissue and surrounding organs [2]. A non-invasive means for accurate
determination of patient eligibility for focal prostate cancer therapy could be of
substantial clinical value and an important step toward reduction of over-diagnosis and
treatment.
The determination of whether a patient is a candidate for focal therapy depends in
part on prognosis, which is multi-factorial and known to be related to the tumour burden
(i.e. the total volume of cancer), as well as Gleason grades of the tumours [5]. In addition,
knowledge of the volumes and spatial distribution of tumours enables an assessment of
the feasibility of focal therapy delivery effectively and safely. Biopsy yields
approximately one dozen cylindrical 1 mm × 18 mm tissue samples and therefore
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provides a tenuous estimate of tumour burden only under a strong set of assumptions.
Emerging evidence suggests that multiparametric magnetic resonance imaging (MPMRI),
with its morphological and functional pulse sequence capabilities, may permit accurate
assessment of prostate cancer burden [6, 7], with implications for screening and targeting
treatment. Typical pulse sequences used for prostate cancer imaging include T2-weighted
(T2W), diffusion-weighted (DW) and dynamic contrast enhanced (DCE) images [8]. The
accuracy of 1.5T MRI for prostate tumour volume determination has previously been
measured for T2W and MR spectroscopic imaging [9] and for T2W, DCE, and DW
imaging [10]. In both studies, the accuracy of MRI-measured tumour volumes was
evaluated against a histopathologic reference standard, with spatial correspondence
between MRI and histology established by qualitative image inspection or by a grid
method. The accuracy and inter-observer variability of prostate tumour volume
estimation based on separate expert contouring of each of the T2W, DCE, and DW MRI
sequences acquired using an endorectal coil at 3T is currently unknown.
The objective of our study was to measure the accuracy, inter-observer variability,
and inter-sequence variability of prostate tumour volume estimation based on contouring
of T2E, DCE, and DW MRI acquired at 3T using an endorectal receive coil. Our
reference standard for accuracy is based on a high-accuracy 3D histology reconstruction
and registration to in vivo MRI [11], corresponding the MRI with adjusted NN-based
reference standard histology tumour volumes. The method for 3D histology
reconstruction and registration to in vivo MRI was developed by another member of our
laboratory and is out of the scope of this thesis.

3.2

Materials

3.2.1 Materials and imaging
This study was approved by the human subject research ethics board of our
institution, and written informed consent was obtained from all patients. The source
population includes 10 patients who underwent radical prostatectomy between April 2010
and December 2011, selected from patients with biopsy-proven prostate cancer by three
collaborating urologists/surgical oncologists. The inclusion criteria were: (1) age 18 years
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or older, (2) clinical stage T1 or T2 prostate cancer histologically confirmed by biopsy,
and (3) suitable for and consenting to radical prostatectomy. The exclusion criteria were:
(1) prior therapy for prostate cancer, (2) use of 5-alpha reductase inhibitors within 6
months of the study start, (3) inability to comply with preoperative imaging, (4) allergy to
contrast agents, (5) sickle cell or other anemias, (6) hip prosthesis, (7) sources of artifact
within the pelvis, and (8) contraindications to MRI.
All MR images were acquired using a 3T GE Discovery MR750 (GE Healthcare,
Waukesha, WI, USA). For T2W MRI, a 2D fast spin-echo sequence was used (repetition
time: 4000–13000 msec, echo time: 156–164 msec, bandwidth: ±31.25 kHz, two signals
acquired, field of view: 14 cm, slice thickness: 2.2 mm, slide spacing: 2.2 mm, matrix:
320 × 192, 40 slices, flip angle: 90º). For dynamic contrast enhanced MRI, a 3D spoiled
gradient-recalled echo sequence was used (repetition time: 5.6–5.9 msec, echo time: 2.1–
2.2 msec, bandwidth: ±31.25 kHz, one or two signals acquired, field of view: 14 cm, slice
thickness: 2.8 mm, slice spacing: 1.4 mm, matrix: 256 × 192, 42 slices, flip angle: 15°;
seven volumes acquired at 90 sec per volume). In addition, we acquired apparent
diffusion (ADC) coefficient MR images. To generate ADC images, DW images were
post-processed on the MR750 console. For DW images, a 2D echo-planar sequence was
used (repetition time: 4000 msec, echo time: 70–77 msec, bandwidth: ±125 kHz, three
signals acquired, field of view: 14 cm, slice thickness: 3.3–3.6 mm, slide spacing: 3.3–3.6
mm, matrix: 128 × 256, 20–34 slices, flip angle: 90º). Sample MR images are shown in
Figure 3.1.
After radical prostatectomy, the prostate was fixed in 10% buffered formalin for
48 hours. Each specimen was then transversely sliced into 4.4 mm thick sections. The
sections were paraffin embedded, yielding whole-mount H&E-stained microscope slides,
each containing a single 4 µm-thick section of tissue taken from each block face. The
histology slides were digitized using a ScanScope GL (Aperio Technologies, Vista, CA,
USA) bright field slide scanner.
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(a)

(b)

(c)

Figure 3.1. Samples of (a) T2W, (b) DCE, (c) ADC MPMRI for one patient; note the
lesion in the bottom left of each image.

3.3

Tumour contouring
Three observers (a radiology resident, a radiology fellow, and a radiologist, all

involved in prostate MRI reporting and research) assessed the MPMRI using the PIRADS system [12] and delineated observed lesions separately on the T2W, DCE, and
ADC images. All observers were blinded to the histology during the contouring. An
experienced clinician, blinded to the MRI, contoured and graded all lesions on histology
each image using the ScanScope ImageScope v11.0.2.725 software (Aperio
Technologies, Vista, CA, USA) using a Cintiq 12WX pen-enabled display (Wacom Co.
Ltd., Saitama, Japan); these contours were reviewed and edited as necessary by a
genitourinary pathologist. Figure 3.2 shows contouring for one patient.
(a)

(b)

(c)

(d)

Figure 3.2. (a-c) Lesion contours from three different observers on the same T2W image.
(d) Corresponding post-prostatectomy histology with lesion contoured. Light green:
Gleason 3+4. Dark green: Gleason 3+3. Brown: Gleason 4+3. Yellow: Gleason 4+4.
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3.4

Methods

3.4.1 Tumour volume calculation
On MPMRI, tumour volume was calculated as the number of voxels within each
3D contoured region, multiplied by the voxel size in mm3. On histology, volume was
measured by first multiplying the cross sectional area of each contoured region on each
slide by the inter-slide spacing of 4.4 mm [hereinafter referred to as a nearest neighbour
(NN) interpolation approach]. Due to the large inter-slide spacing, this approach implies
implausible tumour surfaces having sharp transitions (Figure 3.3(a)). We have previously
demonstrated [13] that a level set (LS)-based through-slide interpolation can produce
smoother tumour surfaces (Figure 3.3(b)); these volumes may be more reasonably
comparable to those defined on MRI (Figure 3.3(c)). We showed that the tumour
volumes given by the LS approach can be estimated based on those given by the simpler
NN approach using a linear regression ($+,- . =  //,- . + 1) where
 = 0.58, 1 = −2.2 for tumours occupying only one slide, and  = 0.82, 1 = −7.5 for
tumours occupying multiple slides [13]. In this work, we adjusted the calculated NN
volumes according to these formulae, and then multiplied by a tissue shrinkage factor of
1.2 to compensate for shrinkage due to formalin fixation and tissue processing.
(a)

(b)

(c)

Figure 3.3. Tumour volume enclosed by (a) nearest-neighbour and (b) level set-based
interpolation of histology contours. (c) Corresponding tumour surface from MRI
contours.
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3.4.2 Imaging-histology correspondence
Digitized histology images were reconstructed to the context of an ex vivo MRI
acquired prior to sectioning using a submillimetre-accurate 2D-3D affine registration
algorithm [11], and subsequently deformably co-registered to in vivo MPMRI via an
interactive thin-plate spline approach with an overall error of 2 mm, measured as the
post-registration misalignment of manually identified homologous intrinsic fiducial
landmarks. The above steps were performed by another member of our laboratory and
their details are out of the scope of this thesis.
Interactive exploration of the fused imaging and histology volumes was
performed to establish correspondence between each contoured tumour on MPMRI and
its corresponding contoured tumour on histology; only contoured MPMRI regions having
corresponding histology tumours (i.e. true positives on MPMRI) were used in this study.

3.4.3 Statistical analysis
Due to small sample size, this is a hypothesis-generating study and therefore
descriptive statistics were reported. We quantified error for each tumour as the MPMRI
tumour volume measurement minus the histology tumour volume measurement; positive
error values represent an overestimation of volume on MRI. To measure inter-observer
and inter-sequence variability of tumour volume estimation on MPMRI, we selected the
six tumours that were contoured by all three observers on all three sequences, where at
least one MPMRI contouring of each tumour corresponded spatially to a histologydefined tumour. For each such tumour, we measured the standard deviation of the
MPMRI volumes estimated by the three observers, and reported the inter-observer
variability as the average of these standard deviations for the T2W, DCE, and ADC
sequences separately. For each tumour, we measured the standard deviation of the
MPMRI volumes given by each observer’s contouring of that tumour on T2W, DCE, and
ADC sequences, and reported the average of these standard deviations as the intersequence variability.
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3.5

Results
The aggregate measurements of MPMRI tumour volume accuracy are provided in

Table 3.1, with detailed results for each tumour in Figure 3.4. Overall, the MPMRI
tumour volumes were overestimates of the histology tumour volumes, with the ADC
maps providing the closest estimates and the DCE volumes providing the best correlation
with histology volumes. For the MPMRI observer variability experiment, the tumour
volume estimates are shown in Figure 3.5. The overall measured inter-observer
variabilities were 245 mm3, 196 mm3, and 238 mm3 for the T2W, DCE, and ADC
sequences, respectively. The measured inter-sequence variabilities were 277 mm3, 329
mm3, and 320 mm3 for observers 1, 2, and 3, respectively. The overall inter-sequence
variability given by pooling all of the observers was 309 mm3; detailed results are given
in Figure 3.6. With the exception of one tumour, the average volume estimates on DCE
were lower than those for T2W and ADC. The agreement between observers on each
pulse sequence was superior to the inter-pulse sequence agreement even within individual
observers.

Table 3.1. Differences between MPMRI and histology tumour volume estimates.

T2W
DCE
ADC

#
Tumours

D = MRI vol. - hist. vol.

27
24
27

907 ± 1804 mm3
1138 ± 2118 mm3
871 ± 1537 mm3

8000

93% (25/27)
88% (21/24)
85% (23/27)

MRI vol. / hist. vol.

Pearson’s corr.

(median)

(MRI vol.– hist.
vol.)

2.9
2.8
2.6

0.64 (p < 0.001)
0.93 (p < 0.001)
0.81 (p < 0.001)
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Figure 3.4. MPMRI and histology(b)tumour volume estimates for (a) T2W, (b) DCE, (c)
ADC.
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Figure 3.5. MPMRI volumes of six tumours delineated by three observers on (a) T2W,
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Figure 3.6. Mean±std tumour volume across all observers for each sequence.

3.6

Discussion
This is the first study measuring accuracy and variability in prostate tumour

volume estimation on MPMRI at 3 Tesla, using separate contouring on T2W, DCE, and
ADC. Tumour volume error estimation was supported by a highly accurate MPMRIhistology image registration and a smooth interpolation of planimetric tumour
measurements on histology.
Prostate tumour volumes estimated based on multi-parametric MRI (T2W, DCE,
ADC) consistently overestimated reference tumour volumes defined by a smooth
interpolation of planimetric tumour contours on digitized histology images. Variability of
tumour volume estimates across the different pulse sequences exceeded inter-observer
variability within any sequence. Tumour volume estimates on DCE MRI provided the
lowest inter-observer variability and the highest correlation with histology tumour
volumes, whereas ADC provided the lowest volume estimation error. If validated on a
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larger data set, the observed correlations could support the development of a correction
scheme for estimation of tumour burden based on MPMRI volume estimates. These
results may also be valuable to informing the design and validation of algorithms for
automated segmentation of prostate tumours on MPMRI.
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Chapter 4
4

Summary and discussion
This thesis summarized the importance of prostate tumour volume measurement

and its use in the appropriate therapy selection for each individual patient. Assessment of
accurate pathologic reporting including assessment of tumour volume in the postprostatectomy specimen is important to determining the need of life-saving adjuvant
therapy. In addition, prostate tumour volume measurement can be used to evaluate the
suitability and feasibility of focal therapy, which can potentially spare patients the
deleterious side effects of radical treatment.
Since reliable estimates of histologic tumour volume require a well-motivated
method to inter-slide tumour boundary interpolation, we have implemented a 3D
reconstruction algorithm that utilizes smooth interpolation and extrapolation to
reconstruct prostate tumour volumes from prostate 2D digital histology images.
Specifically, we have implemented a LS-based through-slide interpolation method to
estimate prostate tumour volumes and compared its estimates to those given by the
planimetric NN-based interpolation method. In addition, the relationships between the
tumour volumes estimated using NN and LS-based interpolation methods, and the
maximum tumour diameter (MTD), estimated square area (ESA), and cubic volume (CV)
methods to tumour size estimation were investigated. We measured the accuracy of the
LS-based interpolation method for tumour boundary interpolation in comparison to the
NN method by reconstructing prostate tumour volumes with different shapes using 3D
MRI tumours as a reference standard. Furthermore, we have measured the accuracy of
tumour area estimation using NN and LS-based interpolation methods using 2D
histology-defined tumours as another reference standard. We also assessed the sensitivity
of histologic tumour volume estimation to inter-slide spacing. Specifically, we estimated
the standard deviation of the tumour volume estimates using a practical range of different
inter-slide spacing values.
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These experiments produced the following main conclusions in Chapter 2:
1) The LS-based interpolation method on digital histology images produces
smoother 3D tumour surfaces that may be more biologically plausible, as
compared to those produced via the NN-based interpolation method.
2) The NN method on digital histology images produces larger tumour volumes,
compared to the LS method, by a median factor of 2.3.
3) Where tumour volume is of interest, the volumes calculated via the NN-based
interpolation method, which is more translatable to a clinical workflow, can be
linearly adjusted to those calculated via the LS-based interpolation method on
digital histology images. However, where tumour boundary localisation is
important, the LS-based approach provides a more plausible boundary.
4) Where simpler tumour volume estimation methods based on linear measurements
are to be used, it is advisable to use, at minimum, a two-dimensional measurement
such as the ESA approach, as opposed to a one-dimensional measurement of
tumour diameter.
5) There is a linear relationship between MRI reference tumour volumes and MRI
tumour volumes estimated via the NN and LS-based interpolation methods. In
addition, we observed tighter limits of agreement between the LS-based volume
estimates and the MRI reference standard, as compared to the NN-based volume
estimates.
6) There is a linear relationship between 2D histology-defined reference standard
tumour areas and 2D histology tumour areas estimated via NN and LS-based
interpolation methods. In addition, we observed tighter limits of agreement
between the LS-based area estimates and the histologic reference standard, as
compared to the NN-based area estimates.
7) Optimal inter-slide spacing involves a compromise between the consistency of
volume estimation given by smaller spacing and the cost and practical challenges
associated with histotechnical handling of thin whole-mount slices. The
variability of histologic tumour volume estimation decreases with decreased interslide spacing, and this variability increases sharply for inter-slide spacing larger
than 5 mm.
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We used our level set based histologic tumour volume estimates to evaluate prostate
tumour volumes estimated based on expert observers’ contouring of MPMRI.
Specifically, we measured the accuracy, inter-observer variability, and inter-sequence
variability of radiologists’ tumour volume estimates on T2W, DCE, and ADC images
acquired at 3 T using an endorectal receive coil by comparison to a histologic reference
standard.
These experiments produced the following main conclusions in Chapter 3:
1) Tumour volumes measured on MPMRI consistently overestimated the
histological reference tumour volumes as measured via LS-based interpolation on
digital histology images.
2) Tumour volumes estimated on DCE MRI provided the highest correlation with
histology tumour volumes, whereas tumour volumes estimated on ADC maps
provide the closest estimates of the histology tumour volumes.
3) The average tumour volume estimated on DCE images is lower than the tumour
volumes estimated on T2W and ADC images.
4) Inter-sequence variability in tumour volume estimation exceeded inter-observer
variability.
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Chapter 5
5

Future work
Future work stemming from this thesis includes: (1) the reconstruction of 3D

histology tumour volumes from non-parallel digitized 2D histology slides; (2) studying
the effect of confounders such as atrophy, benign prostatic hyperplasia (BPH) and
prostatic intra-epithelial neoplasia (PIN) on the appearance of lesions and their
surrounding areas on MRI; and (3) studying the impact of inter-observer and intersequence variability in tumour contouring on histologic tumour coverage for focal
therapy planning.
Some 3D histology reconstruction approaches assume that adjacent histology
slides are parallel and evenly spaced only micrometers apart, and attempt to correct the
deformations resulting from the histology acquisition procedure by aligning adjacent
slides based on anatomical similarity or aligning each slide to a reference image taken
during serial sectioning in a standard reference frame [1-3]. Other approaches include
guiding specimen slicing to obtain histology slides with known positions and orientations
[4], or using reference images taken throughout cutting, or from the sections before
embedding or after the sectioning process [5]. However, these approaches are generally
not compatible with clinical pathology processes. Due to several aspects of the clinical
pathology process, prostate tissue histology sections are not generally parallel and equally
spaced [6]. Histology slides are typically spaced every 3–5 mm and a single histology
section is taken from each slide to save as much tissue as possible for later diagnosis if
necessary. In addition, sections are typically cut in clinical facilities by hospital
histotechnologists, with accompanying operator variability. These constraints break
assumptions used by parallel slide reconstruction: adjacent slides are spaced millimeters
apart and are generally not parallel [6], and the clinical pathology laboratory environment
does not have the facilities for acquiring reference images (e.g. block face images) during
sectioning. Thus, to support smooth tumour shape interpolation in the context of an
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accurate 3D histology reconstruction [7], an interpolation approach that does not assume
parallel slides would be valuable.
Differentiation of prostate cancer from benign confounders such as atrophy, BPH
and prostatic intraepithelial neoplasia (PIN) is an important challenge to accurate MRIbased assessment of tumour burden [8, 9]. Atrophy occurs frequently in the prostates [10]
of older men, and also is one of the most frequent histologic mimics of prostatic
adenocarcinoma. With atrophy, some of the normal characteristics of the prostate glands
are lost. BPH begins in the transition zone and grows inward toward the prostate core,
tightening the urethra. Finally, PIN is essentially the finding of cells having a malignant
appearance on the inside of the gland. Some PIN cells break through the basement
membrane into the surrounding tissue and become invasive, whereas some PIN does not
progress to cancer [10].
Separating these confounders from prostate cancer is challenging on MRI, and the
current Prostate Imaging Reporting and Data Standard (PI-RADS) guidelines for prostate
MRI interpretation do not provide guidelines regarding differentiating between specific
confounders and prostate cancer [11]. In conjunction with a co-registered 3D histologic
reference standard, imaging characteristics of these confounders on the different MRI
sequences could be used to improve the PI-RADS standard and, subsequently increase
reader performance in prostate tumour volume estimation and boundary delineation.
The accurate and repeatable delineation of dominant lesions on MPMRI is critical
and challenging for enabling the clinical application of focal therapy, maximizing the
treatment while minimizing damage to surrounding healthy tissue and nearby organs. It
has been shown that tumour boundaries extended into the central zone may have been
partially obscured by adjacent benign hyperplastic tissue. We observed substantial interobserver and inter-sequence variability in tumour volume estimation on MPMRI. This
variability injects uncertainty into clinical investigations of focal therapy, and may
represent a barrier to the clinical implementation of focal therapy using MPMRI. It
remains to be seen whether this variability has a clinically important impact on the
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resulting histologic tumour coverage of focal therapy plans, and this would be an
important question to study in the future.

5.1

References

1.

Andreasen, A., Drewes, A. M., Assentoft, J. E., and Larsen, N. E., Computerassisted alignment of standard serial sections without use of artificial landmarks.
A practical approach to the utilization of incomplete information in 3-D
reconstruction of the hippocampal region. 1992. 45 (3): p. 199-207

2.

Verbeek, F., Three-dimensional reconstruction of biological objects from serial
sections including deformation correction. Delft Technical University 1995.

3.

Alic, L., et al., Facilitating tumor functional assessment by spatially relating 3D
tumor histology and in vivo MRI: image registration approach. PLoS One, 2011.
6(8): p. e22835.

4.

Chen, L.H., Ho, H., Lazaro, R., Thng, C. H., Yuen, J., Ng, W. S., and Cheng, C.,
Optimum slicing of radical prostatectomy specimens for correlation between
histopathology and medical images. Int J Comput Assist Radiol Surg 2010. 5(5):
p. 471-87.

5.

Jackson, A.S., et al., Dynamic contrast-enhanced MRI for prostate cancer
localization. Br J Radiol, 2009. 82(974): p. 148-56.

6.

Gibson, E., et al., 3D prostate histology image reconstruction: Quantifying the
impact of tissue deformation and histology section location. J Pathol Inform,
2013. 4: p. 31.

7.

Gibson, E., et al., Registration of prostate histology images to ex vivo MR images
via strand-shaped fiducials. Journal of Magnetic Resonance Imaging, 2012.

8.

Hoeks, C.M., et al., Transition zone prostate cancer: detection and localization
with 3-T multiparametric MR imaging. Radiology, 2013. 266(1): p. 207-17.

74

9.

Bratan, F., Niaf, E., Melodelima, C., Chesnais, A. L., Souchon, R., MegeLechevallier, F., Colombel, M., and Rouviere, O., Inuence of imaging and
histological factors on prostate cancer detection and localisation on
multiparametric MRI: a prospective study. Eur Radiology 2013: p. 1-11.

10.

G.J.S. Litjens, R.E., N. Shih, M. Feldman, J.O. Barentsz, C.A. Hulsbergen - van
de Kaa, I. Kovacs, H.J. Huisman and A. Madabhushi, Distinguishing prostate
cancer from benign confounders via acascaded classifier on multi-parametric
MRI., in SPIE Medical Imaging 2014: Computer-Aided Diagnosis2014.

11.

Barentsz, J.O., et al., ESUR prostate MR guidelines 2012. Eur Radiol, 2012.
22(4): p. 746-57.

75

Appendix
Permission
Subject: Request for getting permission
From: Mehrnoush Salarian
To: reprint_permission
Date: Friday, April 11, 2014 1:00 PM
Dear Mehrnoush,
Thank you for seeking permission from SPIE to reprint material from our
publications. As author, SPIE shares the copyright with you, so you retain the right to
reproduce your paper in part or in whole.
Publisher's permission is hereby granted under the following conditions:
(1) the material to be used has appeared in our publication without credit or
acknowledgment to another source; and
(2) you credit the original SPIE publication. Include the authors' names, title of paper,
volume title, SPIE volume number, and year of publication in your credit statement.
Sincerely,
Karen Thomas for
Eric Pepper, Director of Publications
SPIE
Hello,
My name is Mehrnoush Salarian from The University of Western Ontario, Canada. I have
submitted two papers of my work to SPIE Medical Imaging conference on 2013 and
2014. I presented these two papers in Orlando and San Diego, respectively.
Now, I am writing my thesis to finish my Master's. As I understood, I need
a permission to use my two previous published papers. Could you please let me what
should I do to get this permission. You can see my two papers’ information as follows:
My SPIE 2013 paper's title: Toward quantitative digital histopathology for prostate
cancer: comparison of inter-slide interpolation methods for tumour measurement
Proc. SPIE 8676, Medical Imaging 2013: Digital Pathology, 86760F (March 29, 2013);
doi:10.1117/12.2007103

My SPIE 2014 paper's title: Accuracy and variability of tumour burden measurement on
multi-parametric MRI

76

Proc. SPIE 9041, Medical Imaging 2014: Digital Pathology, 90410I (March 20, 2014);
doi:10.1117/12.2043716

Thank you so much in advance.
Regards,
Mehrnoush

77

Curriculum vitae

Mehrnoush Salarian
The University of Western Ontario
London Regional Cancer Centre
EDUCATION:

May 2012 – Present
Master’s Student, Biomedical Engineering, Imaging
The University Of Western Ontario, Biomedical Engineering Graduate
Program, London, Ontario, Canada
Thesis Title: “Prostate Tumour Volume Measurement on Digital Histopathology
and MRI”
Supervisor: Dr. Aaron D. Ward
Advisory committee members: Dr. Aaron Fenster and Dr. Glenn S. Bauman
GPA: 3.8 / 4

September 2009 – January 2012
M.Sc., Biomedical Engineering, Bioelectric Engineering
Amirkabir University of Technology, Faculty of Biomedical Engineering
(Center of Excellence), Tehran, Iran
Thesis Title: “A System for the Assessment and Processing of Infant Cry to
Recognize Pathologies in Recently Born Babies”
Supervisor: Dr. Mohammad Hasan Moradi
Co-Supervisor: Dr. Mansour Vali
September 2003 – July 2008
B.Sc., Electrical Engineering, Electronic Engineering

78

South Tehran Branch, Islamic Azad University (IAU), Tehran, Iran
Thesis Title: “Real-Time ECG Transmission via Computer for Non-Clinical
Applications”
Supervisor: Dr. Ali Farokhi
GPA: 16.31 / 20

HONORS AND AWARDS:

• Western Graduate Research Scholarship (WGRS) and Western Graduate
Research Scholarship International (WGRSI) (May 2012–April 2014)
• Ranked 150th in the nationwide entrance exam of Iran among more than 30,000
participants, June 2009
• Ranked 2nd among 300 Electrical Engineering, Electronic Engineering
students, South Tehran Branch in Spring 2007 semester with GPA of 18.02/20
• Top student among 300 Electrical Engineering, Electronic Engineering
students, South Tehran Branch in Fall 2003 and Winter 2003 semesters with GPA
of 17.20/20 and 18.08/20, respectively.

RESEARCH EXPERIENCE:

•

Image-Guided Cochlear Implant Surgery
Image-Guided Intervention Course, Winter 2013
Instructor: Dr. Terry Peters

• 3D Registration of The Time Series of the Prostate Dynamic ContrastEnhanced Magnetic Resonance Images to Each Other
Advanced Image Processing and Analysis Course, Winter 2013
79

Instructor: Dr. Aaron D. Ward
•

An Iris Recognition Based on Dual Tree Complex Wavelet Transform
Advanced Digital Signal Processing Course, Spring 2010
Instructor: Dr. Farshad Almasganj

•

High-Resolution Cry Analysis in Preterm Newborn Infants
Biomedical Signal Processing Course Project, Winter 2010
Instructor: Dr. Mohammad Hasan Moradi

• A Comparative Analysis of Fundamental Frequency Estimation Methods
with Application to Pathological Voices
Biomedical Signal Processing Course Project, Winter 2010
Instructor: Dr. Mohammad Hasan Moradi
•

Real-Time ECG Transmission via Computer for Non-clinical Applications
Bachelors Degree Thesis Project, Summer 2008
Supervisor: Dr. Ali Farokhi

RELEVANT COURSES:

•
•
•
•
•
•
•
•
•
•
•
•

Advanced Image Processing and Analysis
Introduction to Digital Image Processing
Principles of Communication and Knowledge
Research Ethics and Biostatistics
Biomedical Signal Processing
Digital Signal Processing
Advanced Digital Signal Processing
Neural Network
Physiology
Anatomy
Bioinstrumentation
Electrophysiology

80

TEACHING EXPERIENCE:

• Process Dynamic and Control:
The University Of Western Ontario, London, Ontario, Canada, Winter
2014
• C++ Programming Fundamentals for Engineers:
The University Of Western Ontario, London, Ontario, Canada, Winter
2013
• Electronic 1:
Sama Technical and Vocational Training School, Islamic Azad University,
Noor Branch, Noor, Iran, Fall 2010
•

Linear Control Systems:
Maziar University, Noor, Iran, Spring 2009

PUBLICATIONS:

Conference Presentations:
Oral Presentation:

• Salarian M., Gibson E., Shahedi M., Gaed M., Gomez J. A., Moussa M.,
Romangnoli C., Cool D. W., Bastian-Jordan M., Chin J., Bauman G. S., and Ward
A. D., "Accuracy and variability of tumour burden measurement on multiparametric MRI", SPIE Medical Imaging, San Diego, California, USA (February
16-21, 2014).
• Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,
Bauman G. and Ward A., "Imaging Validation and Quantitative Pathology for
Prostate Cancer Treatment Planning: Shape Interpolation Methods for Tumour
Measurement", CARO COMP Joint Scientific Meeting, Montreal, Quebec,
Canada (September 18-21, 2013).
81

• Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,
Bauman G. and Ward A., "Toward Quantitative Digital Histopathology for
Prostate Cancer: Comparison of Inter-Slide Interpolation Methods for Tumour
Measurement", SPIE Medical Imaging, Orlando, Florida, USA (February 9-14,
2013).
• Salarian M., Vali M. and Moradi M. H., "Classification of Pain and Hunger
Cries of Infants", Iranian Conference on Electrical Engineering (ICEE),
Tehran, Iran (May 15-17, 2012).
• Molaeezadeh S. F., Salarian M. and Moradi M. H., " Type-2 Fuzzy Pattern
Matching for Classifying Hunger and Pain Cries of Healthy Full-term Infants",
The 16th CSI International Symposium on Artificial Intelligence and Signal
Processing (AISP), Shiraz, Iran (May 2-3, 2012).
Poster Presentation:
• Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,

Bauman G. S., and Ward A. D., " Accuracy and variability of tumour burden
measurement on multi-parametric MRI ", Imaging Network Ontario
(ImNO) Symposium, Toronto, Ontario, Canada (March 24-25, 2014).
•

Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,
Bauman G. and Ward A., "Toward Quantitative Digital Histopathology for
Prostate Cancer: Comparison of Inter-Slide Interpolation Methods for Tomour
Measurement", Imaging Network Ontario (ImNO) Symposium, Toronto,
Ontario, Canada (February 4-5, 2013).

•

Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,
Bauman G. S., and Ward A. D., "Development of Quantitative Digital
Histopathology methods for Prostate Cancer Tumour Measurements", London
Health Research Day, London, Ontario, Canada (June 13, 2013).

•

Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M., Cool
D. W., Romagnoli C., Bauman G. S., and Ward A. D., "Imaging Validation
and Quantitative Pathology for Prostate Cancer Treatment Planning: Shape
Interpolation Methods for Tumour Measurement", Oncology Research and
Education Day, London, Ontario, Canada (June 21, 2013).

•

Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M., Cool
D. W., Romagnoli C., Bauman G. S., and Ward A. D., "Imaging Validation
82

and Quantitative Pathology for Prostate Cancer Treatment Planning: Shape
Interpolation Methods for Tumour Measurement", Canadian Cancer
Research Conference, Toronto, Ontario, Canada (November 3-5, 2013).
•

Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,
Bauman G. and Ward A., "Toward Quantitative Digital Histopathology for
Prostate Cancer: Comparison of Inter-Slide Interpolation Methods for Tumour
Measurement", 5th Annual "Imaging Applications in Prostate Cancer"
Workshop, London, Ontario, Canada (November 16, 2012).

Journal Paper:

•

Salarian M., Shahedi M., Gibson E., Gaed M., Gomez J. A., Moussa M.,
Cool, D., Romagnoli, C., Bauman G. and Ward A., "Toward Quantitative
Digital Histopathology for Prostate Cancer: Comparison of Inter-Slide
Interpolation Methods for Tumour Measurement", SPIE Journal of Medical
Imaging, 2014 (in preparation).

83

